SAN DIEGO, April 24, 2024 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that the GoodRx class action lawsuit seeks to represent purchasers or acquirers of GoodRx Holdings, Inc. (NASDAQ:GDRX) common stock between September 23, 2020 and November 8, 2022, inclusive (the "Class Period"). Captioned Barsuli v. GoodRx Holdings, Inc., No. 24-cv-03282 (C.D. Cal.), the GoodRx class action lawsuit charges GoodRx and certain of GoodRx's top executives and directors with violations of the Securities Exchange Act of 1934.
If you suffered substantial losses and wish to serve as lead plaintiff of the GoodRx class action lawsuit, please provide your information here:
https://www.rgrdlaw.com/cases-goodrx-holdings-inc-class-action-lawsuit-gdrx.html
You can also contact attorneys J.C. Sanchez or Jennifer N. Caringal of Robbins Geller by calling 800/449-4900 or via e-mail at info@rgrdlaw.com.
CASE ALLEGATIONS: GoodRx operates a price comparison platform for prescription drugs which, in many cases, offers consumers access to lower prices (through discount codes and coupons) for their medications. GoodRx also generates a portion of its revenue from subscription plans like the "Kroger Rx Savings Club," which provides "access [to] lower prescription prices at" pharmacies operated by The Kroger Co.
The GoodRx class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (i) while Kroger accounted for less than 5% of the pharmacies accepting GoodRx discounts, Kroger was responsible for nearly 25% of GoodRx's total prescription transactions revenue (Kroger's primary revenue stream); and ...